Inhibikase Therapeutics Debt-to-Assets Ratio Growth & History (IKT)

Inhibikase Therapeutics's debt-to-assets ratio was 0.00 for fiscal 2025.

View full Inhibikase Therapeutics company overview

Inhibikase Therapeutics annual debt-to-assets ratio history

Inhibikase Therapeutics annual debt-to-assets ratio

Fiscal yearPeriod endedDebt-to-assets ratioChangeGrowth
20252025-12-310.00−0.00
20242024-12-310.00−0.05−95.43%
20232023-12-310.050.02+74.23%
20222022-12-310.030.02+380.73%
20212021-12-310.01

Inhibikase Therapeutics debt-to-assets ratio trends

Between the periods ended 2021-12-31 and 2025-12-31, Inhibikase Therapeutics's debt-to-assets ratio decreased from 0.01 to 0.00, a change of −0.01. The latest reported quarter, Q2 2026, shows 0.00.

About the metric

What the debt-to-assets ratio means

The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.

Calculation and source

How debt-to-assets is calculated

TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Inhibikase Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about IKT yet. Start the conversation.

Write the first post